Effectiveness of clinical pathway for treatment of advanced schistosomiasis hepatic fibrosis
10.16250/j.32.1374.2016272
- VernacularTitle:晚期血吸虫病抗肝纤维化治疗临床路径的实施效果观察
- Author:
Xuehua NIU
;
Haiyong HUA
;
Wenjian GUO
;
Ye HONG
;
Lu YOU
;
Yong DENG
;
Wei CHEN
- Keywords:
Advanced schistosomiasis;
Hepatic fibrosis;
Clinical pathway;
Effectiveness evaluation
- From:
Chinese Journal of Schistosomiasis Control
2017;29(4):475-477
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the effectiveness of the clinical pathway for the treatment of advanced schistosomiasis he-patic fibrosis. Methods The duration of hospital stay,gross hospitalization expense,individual-paid expense,interior diame-ter of portal vein,levels of four serum hepatic fibrosis-related parameters(PIIIP,CIV,HA,and LN),and activities of ALT, AST andγ-GT were assessed and compared between the advanced schistosomiasis patients receiving the clinical pathway and ones receiving non-clinical pathway. Results There were 142 advanced schistosomiasis patients with hepatic fibrosis receiving the clinical pathway of anti-hepatic fibrosis. Compared with the patients receiving non-clinical pathway ,the gross hospitalization expenses reduced by 11.2％(t=6.310,P<0.05),and the individual-paid expenses reduced by 16.1％(t=4.326,P<0.05). The mean HA level was twice higher than the normal range,with a positive rising from 70.4％to 83.1％,and the abnormal rates of CIV andγ-GT were 64.1％and 28.9％respectively. Conclusions The clinical pathway can drastically reduce the treatment expenses in advanced schistosomiasis patients with hepatic fibrosis. However,the patients have a trend towards the persistent disease progression. Therefore,the researches of more effective therapeutic methods for advanced schistosomiasis hepatic fibro-sis are urgently needed.
